We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

87 hedge funds and large institutions have $111M invested in iShares US Pharmaceuticals ETF in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

21.29% more ownership

Funds ownership: 81.21% → 102.5% (+21%)

7% more capital invested

Capital invested by funds: $104M → $111M (+$7.14M)

4% less funds holding

Funds holding: 91 → 87 (-4)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

59% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 37

Holders
87
Holders Change
-4
Holders Change %
-4.4%
% of All Funds
1.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
37
Closed
15
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$522K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$22.2M
2
Jane Street
Jane Street
New York
+$4.83M
3
SCP
Syntal Capital Partners
Texas
+$2.63M
4
SPIA
Steward Partners Investment Advisory
New York
+$804K
5
DS
DRW Securities
Illinois
+$589K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.29M
2
Ameriprise
Ameriprise
Minnesota
-$3.93M
3
KCM
Karp Capital Management
California
-$2.93M
4
AWA
ARS Wealth Advisors
Florida
-$2.5M
5
Morgan Stanley
Morgan Stanley
New York
-$1.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
RJFSA
26
Raymond James Financial Services Advisors
Florida
$779K +$2.67K +54 +0.3%
TYCC
27
Texas Yale Capital Corp
Florida
$725K -$713K -14,430 -50%
JP Morgan Chase
28
JP Morgan Chase
New York
$620K -$2.08K -42 -0.3%
LTFS
29
Ladenburg Thalmann Financial Services
Florida
$611K -$16.3K -330 -3%
DS
30
DRW Securities
Illinois
$599K +$589K +11,922 New
FWCM
31
Ferguson Wellman Capital Management
Oregon
$544K -$424K -8,580 -44%
Koshinski Asset Management
32
Koshinski Asset Management
Illinois
$536K -$85.3K -1,725 -14%
BTS
33
BB&T Securities
Virginia
$510K -$891K -18,027 -64%
PAG
34
Pinnacle Advisory Group
Maryland
$500K – – –
RMAM
35
Raab & Moskowitz Asset Management
New Jersey
$483K -$14.7K -297 -3%
JMPWA
36
JP Morgan Private Wealth Advisors
California
$469K -$5.19K -105 -1%
SB
37
Suntrust Banks
Georgia
$450K +$58.9K +1,191 +16%
Ameriprise
38
Ameriprise
Minnesota
$448K -$3.93M -79,404 -90%
WIA
39
Wealthstreet Investment Advisors
Texas
$446K – – –
FAAS
40
First Allied Advisory Services
California
$441K +$28.9K +585 +7%
Cerity Partners
41
Cerity Partners
New York
$413K – – –
TFF
42
The Family Firm
Maryland
$413K +$54.1K +1,095 +15%
Fisher Asset Management
43
Fisher Asset Management
Washington
$405K +$398K +8,061 New
AG
44
Advisor Group
Arizona
$366K -$21.9K -444 -6%
AWA
45
ARS Wealth Advisors
Florida
$349K -$2.5M -50,625 -88%
OC
46
Oppenheimer & Co
New York
$324K – – –
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$312K -$11.1K -225 -3%
Creative Planning
48
Creative Planning
Kansas
$264K +$593 +12 +0.2%
FDCDDQ
49
Federation des caisses Desjardins du Quebec
Quebec, Canada
$249K -$4.45K -90 -2%
Cambridge Investment Research Advisors
50
Cambridge Investment Research Advisors
Iowa
$222K -$12.3K -249 -5%
1
2
3 4 5

IHE Hedge Fund Activity: Q2 2019 in Review

87 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2019, worth a combined $111M — up 6.9% from $104M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of IHE and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 15 added.

The largest buyer was Goldman Sachs, adding an estimated $22.2M. The largest seller was Citadel Advisors, cutting an estimated $4.29M.

  • 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2019, down from 91 in Q1 2019.
  • Funds reported $111M of iShares US Pharmaceuticals ETF stock for Q2 2019, up 6.9% quarter-over-quarter.
  • 11 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2019 and 15 closed out, a net change of -4 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2019 was Goldman Sachs, an estimated $22.2M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2019 was Citadel Advisors, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2019.